Alex Levitzki
10Patents
5h-index
24Co-inventors
66Inventor score
Filing activity: Jan 7, 1994 → Mar 8, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5851999A | FLK-1 is a receptor for vascular endothelial growth factor | Physics | 88 | Expired |
| US6331555A | Treatment of platelet derived growth factor related disorders such as cancers | Human Necessities | 81 | Expired |
| US5700823A | Treatment of platelet derived growth factor related disorders such as cancers | Emerging Cross-Sectional Technologies | 76 | Expired |
| US5990141A | Treatment of platelet derived growth factor related disorders such as cancers | Emerging Cross-Sectional Technologies | 47 | Expired |
| US5700822A | Treatment of platelet derived growth factor related disorders such as cancers | Emerging Cross-Sectional Technologies | 32 | Expired |
| US10543232B2 | Polyplex of double-stranded RNA and polymeric conjugate | Chemistry; Metallurgy | 4 | Active |
| US10278991B2 | Polyethyleneimine polyethyleneglycol vectors | Chemistry; Metallurgy | 3 | Active |
| US11298376B2 | Method of treating cancer | Chemistry; Metallurgy | 1 | Active |
| US7964399B2 | Cell line comprising vector encoding truncated FLK-1 receptor | Physics | 1 | Expired |
| US6872699B2 | Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein | Physics | 1 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.